Recent

% | $
Quotes you view appear here for quick access.

ACADIA Pharmaceuticals Inc. Message Board

  • donboyd10 donboyd10 Oct 15, 2013 10:29 AM Flag

    alpha article

    seeking knowledge from truthful posters here. The article says that pima receptors still has to show it works as designed in the drug. Can knowledgeable posters address this statement by that article today. I am long acad.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • There are areas on individual cells in the body called "receptor sites". These receptors are the specific target of the drug being used. When a drug comes into contact with a receptor site on a cell, chemical and metabolic changes occur within that cell. The changes are the desired effect of the drug. Some people have fewer receptor sites than other people, and are thus more resistant to the drug's effects.

    • Okay, well I'm surprised that Seeking Alpha would even allow a quote like that with zero context. The quote was 'The nondopaminergic blocker of serotonin 5-HT2A receptors still has to show it works as designed in the drug'.

      First, this is just wrong factually. That Phase 3 trial was confirmatory as the second Phase 3 was waved off. In other words, in PDP the efficacy has been established. Actually, we can begin to say that the efficacy has been established to some extent in schizophrenia as well based on Acadia's strong data.

      Now, the part about being a 'blocker of serotonin 5-HT2A receptors' is sloppy talk. Risperidone and Abilify for instance could be called blockers of the serotonin 5-HT2A receptor but Pimavanserin is not just a blocker of this receptor. An inverse agonist (which is what Pimavanserin in) is going to generate an effect opposite of what an agonist would do. So you're not just calming the activity but are basically taking it in the other direction. It's revolutionary stuff. What I'm finding is that so few of these writers actually know the status of Pimavanserin in the clinic. I believe this is because they do their research and see that it has completed just one Phase 3 study so they assume it needs another. Why do they assume this? They assume this because the FDA has never waved off a second Phase 3 in CNS. Until now. In this case, the FDA decided that only one Phase 3 would be enough. That's without precedent in CNS. If there is another case of this then in CNS then I've never heard of it. Anyway, long and strong here.

    • 3 SA articles in just two days pushed the stock from $21.50 to $25 and now it's selling off hard, what good those articles do? except serving agendas of short term traders who are usually behind those articles?

    • my advise is not to make investment decisions based on SA articles, it just provides short term lift to the stock, the purpose of those articles mostly is to take money from newbies who rush into the stock after reading those articles...good luck

 
ACAD
38.36-0.54(-1.39%)Apr 24 4:00 PMEDT